 |
|
Weekly Digest
October 6, 2026
Volume 7, Issue 1
|
|
What’s Inside This Week
California’s new law restricting weight-loss and muscle-building supplement sales to minors headlines the week, fueling industry warnings about a growing state-by-state patchwork even as Congress weighs federal uniformity bills. Trade groups also split publicly over the Dietary Supplement Innovation Act and its proposed fix to DSHEA’s drug preclusion provision, with CRN and AHPA in favor and NPA opposed. Elsewhere, states diverge on kratom and 7-OH rules, UK regulators flag widespread supplement ad compliance risks, the Netherlands proposes herbal restrictions, and SupplySide Global approaches later this month.
|
|
|
|
State Action & the Federal Patchwork
|
California Signs Restrictive Supplement Bill Into Law, Industry Disappointed and Concerned
NutraIngredients-USA | September 29, 2026
Gov. Gavin Newsom signed AB 2030, which bars over-the-counter weight-loss and muscle-building supplement sales to minors without a prescription. Industry groups warned the broad approach could sweep in lawful products such as fiber, protein, and multivitamins. The law adds to state-level rules layered on top of the federal framework Congress set in DSHEA.
|
State Regulatory Surge Far From Over, Experts Say
SupplySide Supplement Journal | October 2, 2026
Experts say California’s action signals a growing wave of state supplement rules, with at least five more states weighing age-restriction bills. NPA’s Daniel Fabricant called the trend an increasingly unworkable patchwork for products already regulated federally. The developments sharpen the case for the federal uniformity legislation pending in Congress.
|
|
|
|
|
|
Drug Preclusion & the Innovation Act
|
Drug Preclusion: Necessary Reform (CRN and AHPA Opinion)
NutraIngredients-USA | October 5, 2026
The Council for Responsible Nutrition and the American Herbal Products Association back the Dietary Supplement Innovation Act (H.R. 10336). They argue it would protect ingredients marketed before 1994 and create clearer thresholds and pathways to lift drug preclusion. The drug exclusion clause is one of the most consequential provisions of DSHEA for ingredient innovation.
|
Drug Preclusion: Consider the Source (NPA Opinion)
NutraIngredients-USA | October 2, 2026
Natural Products Association CEO Daniel Fabricant opposes H.R. 10336, arguing it would write pharmaceutical gatekeeping into federal law by using a Phase 2 or Phase 3 trigger for preclusion. He warns the industry against negotiating away its regulatory independence. The split with CRN and AHPA shows how divided the industry remains on reforming the drug exclusion clause.
|
|
|
|
Enforcement, Marketing & Product Safety
|
Kratom, 7-OH Laws Diverge Amid the Spread of Potent Synthetic Products
Stateline | October 5, 2026
States are taking sharply different approaches to kratom and its synthetic derivative 7-OH. Federal officials moved in July to place 7-OH above a set concentration in Schedule I, exempting naturally occurring botanical kratom. The episode illustrates the line between lawful botanical supplements and concentrated products that draw regulatory action.
|
Thousands of Supplement Ads at Risk of Non-Compliance, ASA Investigation Finds
NutraIngredients-USA | October 5, 2026
The UK Advertising Standards Authority reviewed roughly 309,000 paid wellness ads and found more than 86 percent posed medium or high compliance risk. Mushroom supplements and research peptides were among the categories of greatest concern. The findings are a reminder of the claims scrutiny that U.S. marketers also face under DSHEA and FDA and FTC rules.
|
|
|
|
Global & Industry Outlook
|
Proposed Dutch Supplement Rule Changes Could Force Product Reformulation
NutraIngredients-USA | October 6, 2026
The Netherlands has proposed banning ashwagandha and Huperzia serrata in food supplements, limiting black cohosh dosage, and adding warning labels to a dozen other herbals. Consultation runs until December 7, 2026. The proposal offers a contrast with the U.S. approach under DSHEA, where botanicals are generally marketed without pre-approval.
|
SupplySide Global 2026: Exploring This Year’s Education Sessions
NutraIngredients-USA | October 5, 2026
SupplySide Global runs October 26 to 30 in Las Vegas, with sessions on regulatory compliance, GLP-1 market impact, gut health, and sports nutrition. The regulatory track gives industry a venue to weigh the state, federal, and FDA developments reshaping the supplement market.
|
|
|
|
Your Voice Matters
Federal bills on drug preclusion, product listing, and state preemption are still moving. Tell your members of Congress that a strong, science-based DSHEA framework protects access to safe supplements.
Take Action at DSHEA.org |
© 2026 DSHEA Preservation Alliance. All rights reserved. UnsubscribePowered by PICXM
|